Kodiak Sciences Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
KOD$108.06+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
| Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balances at December 31, 2020 | 51,112,302 | $5 | $1,151,920 | $53 | $(291,227) | $860,751 |
| Issuance of common stock upon exercise of stock options | 463,796 | — | 7,743 | — | — | 7,743 |
| Issuance of common stock upon vesting of restricted stock units | 93,218 | — | — | — | — | — |
| Issuance of common stock pursuant to employee stock purchase plan | 6,958 | — | 484 | — | — | 484 |
| Issuance of common stock upon exercise of common stock warrants | 149,983 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 61,385 | — | — | 61,385 |
| Other comprehensive loss | — | — | — | (53) | — | (53) |
| Net loss | — | — | — | — | (266,990) | (266,990) |
| Balances at December 31, 2021 | 51,826,257 | 5 | 1,221,532 | — | (558,217) | 663,320 |
| Issuance of common stock upon exercise of stock options | 126,999 | — | 1,770 | — | — | 1,770 |
| Issuance of common stock upon vesting of restricted stock units | 103,032 | — | — | — | — | — |
| Issuance of common stock pursuant to employee stock purchase plan | 27,863 | — | 174 | — | — | 174 |
| Issuance of common stock upon exercise of common stock warrants | 249,699 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 106,033 | — | — | 106,033 |
| Other comprehensive loss | — | — | — | (1,307) | — | (1,307) |
| Net loss | — | — | — | — | (333,823) | (333,823) |
| Balances at December 31, 2022 | 52,333,850 | 5 | 1,329,509 | (1,307) | (892,040) | 436,167 |
| Issuance of common stock upon exercise of stock options | 7,528 | — | 60 | — | — | 60 |
| Issuance of common stock upon vesting of restricted stock units | 116,403 | — | — | — | — | — |
| Issuance of common stock pursuant to employee stock purchase plan | 50,821 | — | 182 | — | — | 182 |
| Stock-based compensation expense | — | — | 88,556 | — | — | 88,556 |
| Other comprehensive loss | — | — | — | 1,307 | — | 1,307 |
| Net loss | — | — | — | — | (260,491) | (260,491) |
| Balances at December 31, 2023 | 52,508,602 | $5 | $1,418,307 | $— | $(1,152,531) | $265,781 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.